23.12.2024 14:49:57

Nuvation Bio's NDA For Taletrectinib Gets FDA Priority Review, Stock Up In Pre-Market

(RTTNews) - Nuvation Bio Inc. (NUVB), Monday announced that the U.S. Food and Drug Administration has granted Priority Review for the company's New Drug Application for Taletrectinib and assigned a Prescription Drug User Fee Act date on June 23.

The company explained that the oral, investigational next-generation ROS1 tyrosine kinase inhibitor could be used for the treatment of patients with advanced ROS1-positive non-small cell lung cancer.

The NDA is based on the pooled safety and efficacy data from the pivotal Phase 2 TRUST-I and TRUST-II studies of Taletrectinib.

During the pre-market hours, Nuvation's stock is trading at $2.79, up 4.43 percent on the New York Stock Exchange.

Nachrichten zu Nuvation Bio Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Nuvation Bio Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Nuvation Bio Inc Registered Shs 2,77 4,53% Nuvation Bio Inc Registered Shs